Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place

QR Code

Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place

Aim. To optimize chronic heart failure (CHF) pharmacotherapy, basing on endothelin (ET) system activity, functional and cardio-hemodynamic parameters, and their dynamics in beta-adrenoblocker nebivolol therapy. Material and methods. The study included 52 patients with coronary heart disease and syst...

Full description

Saved in:

Bibliographic Details
Main Authors:	L. I. Olbinskaya, Yu. I. Naymann
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2007-02-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	chronic heart failure pulmonary hypertension endothelin nebivolol
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/1145
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

URODYNAMIC EFFECTS OF BETA-ADRENOBLOCKERS: NEBIVOLOL ADVANTAGES
by: M. P. Savenkov, et al.
Published: (2016-01-01)

THE PLACE OF NEBIVOLOL IN RATIONAL THERAPY OF CONGESTIVE HEART FAILURE
by: A. B. Khadzegova
Published: (2014-09-01)

Differential beta-adrenoblocker therapy in chronic heart failure
by: S. N. Tereshchenko, et al.
Published: (1970-01-01)

RATIONAL CHOICE OF Β-ADRENOBLOCKERS IN CHRONIC HEART FAILURE THERAPY
by: M. L. Maximov
Published: (2015-12-01)

Modern therapeutic potential of super-selective β<sup>1</sup>-adrenoblocker nebivolol
by: V. I. Makolkin, et al.
Published: (1970-01-01)

Benefits of vasodilating beta-adrenoblockers for arterial hypertension treatment
by: V. B. Mychka
Published: (2012-06-01)

NEBIVOLOL – ESPECIAL BETA-ADRENOBLOCKER
by: T. Műnzel, et al.
Published: (2016-01-01)

Microcirculation in arterial hypertension patients receiving beta-adrenoblockers
by: L. L. Kirichenko, et al.
Published: (2006-12-01)

THE ROLE OF ENDOTHELIN-1 IN VASCULAR HEMOSTASIS OF PERIODONTAL TISSUES
by: N.V. Yarychkivska
Published: (2018-03-01)

EXPERIENCE OF USING THE NONSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
by: M. A. Simakova, et al.
Published: (2018-04-01)

Hereditary features of plasma concentrations of endothelin-1 in men with hypertension and chronic heart failure
by: H. O. Palahniuk, et al.
Published: (2016-12-01)

Pleiotropic activity of antihypertensives in atherothrombogenesis. Nebivolol: increasing possibilities and reducing restrictions
by: M. G. Bubnova
Published: (2008-12-01)

AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM
by: T. V. Martynuk, et al.
Published: (2014-03-01)

EFFICACY OF NEBIVOLOL IN TREATMENT OF WOMEN WITH CORONARY HEART DISEASE
by: N. A. Koryagina, et al.
Published: (2014-12-01)

NEBIVOLOL ROLE IN THE CORRECTION OF INTRACARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC HEART FAILURE
by: R. L. Dzhanaeva, et al.
Published: (2012-02-01)

THE EFFECT OF NEBIVOLOL ON BONE MINERAL DENSITY IN POSTMENOPAUSAL WOMEN WITH MILD HYPERTENSION
by: I. L. Tepoyan, et al.
Published: (2015-09-01)

COMPARATIVE PHARMACOKINETICS AND EFFECT ON THE HEMODYNAMICS OF ORIGINAL AND GENERIC NEBIVOLOL IN HEALTHY VOLUNTEERS
by: E. I. Bambysheva, et al.
Published: (2016-05-01)

OPTIMIZATION OF SPECIFIC THERAPY FOR PULMONARY ARTERIAL HYPERTENSION: THE POSSIBILITIES OF USING ENDOTHELIN RECEPTOR ANTAGONISTS
by: T. V. Martynyuk, et al.
Published: (2017-06-01)

Modern views on β-adrenoblocker therapy in elderly patients with chronic heart failure
by: E. V. Privalova
Published: (2007-06-01)

NEBIVOLOL and the 2009 ESH update to the 2007 ESH/ESC Guidelines
by: V. I. Makolkin
Published: (2010-12-01)

OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY
by: V. V. Gramovich, et al.
Published: (2018-12-01)

Nebivolol therapy and reduction of intravascular platelet activity in patients with atrial hypertension and metabolic syndrome
by: I. N. Medvedev
Published: (2006-06-01)

Beta-adrenoblockers in arterial hypertension treatment: focus on nebivolol
by: D. Voytsekhovsky, et al.
Published: (2008-08-01)

EFFECTS OF NEBIVOLOL VS NADOLOL ON GLUCOSE AND LIPID METABOLISM IN OVERWEIGHT HYPERTENSIVE PATIENTS. A OPEN RANDOMIZED CONTROLLED STUDY
by: E. R. Berngardt, et al.
Published: (2003-06-01)

Shear Stress-Dependent Modulation of Endothelin B Receptor: The Role of Endothelial Glycocalyx Heparan Sulfate
by: Camden Holm, et al.
Published: (2025-07-01)

Beta-adrenoblocker nebivolol in the new Russian guidelines on arterial hypertension
by: L. G. Ratova, et al.
Published: (2008-08-01)

REGULATORY-ADAPTIVE STATE IN EVALUATION OF BISOPROLOL AND NEBIVOLOL THERAPY EFFECTIVENESS FOR VENTRICULAR ARRHYTHMIA
by: I. Z. Shubitidze, et al.
Published: (2016-12-01)

HEMODYNAMIC AND METABOLIC EFFECTS OF NEBIVOLOL IN LOCOMOTIVE CREW STAFF WITH NEWLY DIAGNOSED ARTERIAL HYPERTENSION
by: I. V. Osipova, et al.
Published: (2016-01-01)

CLINICAL CASE OF COMBINATION THERAPY INCLUDING AMBRIZENTAN IN THE PATIENT WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: G. A. Movsisyan, et al.
Published: (2017-06-01)

Expression of endothelin in experimental myocardial infarction in a changed concentration of FGF and VEGF
by: M. G. Shurygin, et al.
Published: (2013-02-01)

ENDOTHELINES AND CARDIOVASCULAR PATHOLOGY
by: A. M. Alieva, et al.
Published: (2014-11-01)

Assessment of pleiotropic effects of nebivolol: influence on microcirculation parameters and bone tissue in postmenopausal women with mild arterial hypertension
by: I. L. Tepojan, et al.
Published: (2016-04-01)

NEBIVOLOL IN TREATMENT OF STABLE EXERTIONAL ANGINA PECTORIS
by: Y. V. Gavrilov, et al.
Published: (2015-12-01)

Effect of Curcumin on Nitric Oxide and Endothelin-1 Levels in L-NAME-Induced Preeclamptic Wistar Rat
by: Bambang Rahardjo, et al.
Published: (2024-12-01)

Clinical efficacy of nebivolol and metoprolol in complex treatment of patients with coronary heart disease and II-III functional class chronic heart failure
by: A. G. Evdokimova, et al.
Published: (2005-04-01)

Endothelin-1 level in the tear fluid of children with primary congenital glaucoma
by: L. A. Katargina, et al.
Published: (2023-03-01)

Superselective beta-adrenoblocker Nebivolol in patients with cardiovascular pathology and obstructive pulmonary syndrome
by: S. I. Ovcharenko, et al.
Published: (2006-04-01)

Nebivolol Mitigate the Hepatic Expression Level of Inducible and Endothelial Nitric Oxide Synthase in Tamoxifen-Induced Oxido-Inflammatory Changes in Female Rats
by: Noor Ahmed Hammadi, et al.
Published: (2025-06-01)

The role of nitric oxide in improving endothelial function andcardiovascular health: focus on nebivolol
by: G. L. Bakris, et al.
Published: (2011-04-01)

Nebivolol effects on myocardial remodelling, inflammation markers and endothelial dysfunction in chronic heart failure patients with or without Type 2 diabetes mellitus
by: Yu. N. Belenkov, et al.
Published: (2011-02-01)